NCT06581406: An ongoing trial by Replimune Inc.
This trial is ongoing. It must report results 4 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06581406 |
|---|---|
| Title | A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 17, 2024 |
| Completion date | Jan. 31, 2030 |
| Required reporting date | Jan. 31, 2031, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 3, 2026 |
| Days late | None |